Resources Archive - WuXi Biology

CTHRC1 as a Novel Candidate for Neurodevelopmental Disorders

Cognitive dysfunction affects over 50 million individuals worldwide, with Alzheimer’s disease (AD) representing two-thirds of cases. Due to the complexity...

Peptide Early Discovery Services

Peptide drugs, composed of short chains of amino acids, represent a promising class of therapeutics with unique advantages over traditional...

mTOR Inhibition Enhances Targeted Protein Degradation Efficacy

Targeted protein degradation (TPD) approaches, including molecular glue degraders (MGDs) and proteolysis targeting chimeras (PROTACs), can overcome traditional occupancy-based inhibitor...

ALDH1A2 Inhibition Enhances Antitumor DC Vaccine Efficacy

Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored...

KRAS G12D Inhibitor-induced Resistant Tumor Models

KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25%...

Fully Automated HTS Platform for Screening Diverse Targets

High-throughput screening (HTS) remains a foundational technology in early drug discovery, responsible for identifying approximately one-third of today’s clinical candidates....

Unleashing the Power of Spectral Shift Technology

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...

HTS Platform to Advance Molecular Glue Discovery

Despite major advances in small molecule drug development, most disease-relevant proteins remain beyond the reach of conventional therapeutics. Molecular glues...

R&D Strategies for T Cell Engager Drugs

From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...

Knowledge Library